Genprex, Inc. Files 8-K

Ticker: GNPX · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1595248

Sentiment: neutral

Topics: regulatory-filing, financial-statements

Related Tickers: GNPX

TL;DR

Genprex filed an 8-K, mostly procedural. No major news yet.

AI Summary

Genprex, Inc. filed an 8-K on January 13, 2025, reporting on financial statements and exhibits. The filing does not contain specific financial figures or operational updates but serves as a procedural disclosure. The company is incorporated in Delaware and headquartered in Austin, Texas.

Why It Matters

This filing indicates Genprex, Inc. is meeting its regulatory reporting obligations. Investors should look for subsequent filings for specific operational or financial details.

Risk Assessment

Risk Level: low — The filing is a routine 8-K and does not contain new material information that would immediately impact risk.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing by Genprex, Inc.?

The primary purpose of this 8-K filing is to report on financial statements and exhibits, as well as to make a Regulation FD disclosure and report other events.

When was this 8-K filed by Genprex, Inc.?

This 8-K was filed on January 13, 2025.

Where are Genprex, Inc.'s principal executive offices located?

Genprex, Inc.'s principal executive offices are located at 3300 Bee Cave Road, #650-227, Austin, TX 78746.

In which state was Genprex, Inc. incorporated?

Genprex, Inc. was incorporated in Delaware.

What is the SIC code for Genprex, Inc.?

The Standard Industrial Classification (SIC) code for Genprex, Inc. is 2834, which corresponds to Pharmaceutical Preparations.

Filing Stats: 1,578 words · 6 min read · ~5 pages · Grade level 14.5 · Accepted 2025-01-13 09:00:51

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. Corporate Presentation The investor presentation about Genprex, Inc. (the "Company" or "Genprex") that is furnished as Exhibit 99.1 to this Current Report on Form 8-K may be presented at meetings with investors, analysts, and others, in whole or in part and possibly with modifications, from time to time on or after January 13, 2025. A copy of the investor presentation slides, substantially in the form expected to be used in such presentations and meetings, will be available on the Company's website, www.genprex.com . The information in this Current Report on Form 8-K under Item 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except as shall be expressly set forth by a specific reference in such filing.

01 Other Events

Item 8.01 Other Events. The Company's investor presentation provides certain business updates, including on its oncology and diabetes gene therapy programs. Acclaim-1 Clinical Trial The Acclaim-1 study is a Phase 1/2 clinical trial that has three portions - a Phase 1 dose escalation which has been completed, a Phase 2a expansion, and a Phase 2b randomized portion. The Acclaim-1 trial uses a combination of REQORSA and AstraZeneca's Tagrisso ( osimertinib ) in patients with late-stage Non-Small Cell Lung Cancer ("NSCLC") that has activating epidermal growth factor receptor mutations and progression after treatment with Tagrisso. The Company is currently enrolling and treating patients in the Phase 2a expansion portion of its Acclaim-1 study. The Phase 2a expansion portion of the trial is expected to enroll approximately 33 patients. There will be an interim analysis following the treatment of 19 patients in the Phase 2a portion. The Company expects to complete the enrollment of the first 19 patients for interim analysis in the Phase 2a expansion portion of the study in the first half of 2025 and expects the interim analyses in the second half of 2025. The Acclaim-1 clinical trial has received U.S. Food and Drug Administration ("FDA") Fast Track Designation for the Acclaim-1 treatment combination of REQORSA and Tagrisso in NSCLC patients who have progressed after Tagrisso treatment. Acclaim-3 Clinical Trial The Acclaim-3 study is a Phase 1/2 clinical trial that has two portions - a Phase 1 dose escalation portion which has been completed, and a Phase 2 expansion portion. The Acclaim-3 trial uses a combination of REQORSA and Genentech, Inc.'s Tecentriq ( atezolizumab ) as maintenance therapy for patients with extensive stage Small Cell Lung Cancer ("SCLC") who developed tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment. In December 2024, the Safety Review Committee approved the opening of the Phase 2 expansion portion of

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Investor Presentation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GENPREX, INC. Date: January 13, 2025 By: /s/ Ryan Confer Ryan Confer Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial and Accounting Officer)

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing